Literature DB >> 17062665

Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma.

Ben Davidson1, Zhen Zhang, Lilach Kleinberg, Mei Li, Vivi Ann Flørenes, Tian-Li Wang, Ie-Ming Shih.   

Abstract

PURPOSE: Ovarian/primary peritoneal serous carcinoma (OC/PPC) and diffuse peritoneal malignant mesothelioma (DMPM) are highly aggressive tumors that are closely related morphologically and histogenetically. It remains unclear whether both tumors are molecularly distinct neoplasms. The current study compared global gene expression patterns in OC/PPC and DMPM. EXPERIMENTAL
DESIGN: Ten OC/PPC and five DMPM effusions were analyzed for gene expression profiles using the Affymetrix U133 Plus 2 arrays and the dCHIP analysis program. Differentially expressed candidate genes were validated using quantitative real-time PCR and immunohistochemistry.
RESULTS: Unsupervised hierarchical clustering using all 54,675 genes in the array classified the samples into two groups: DMPM specimens versus OC/PPC specimens. A total of 189 genes that were differentially expressed in these two groups were selected based on statistical significance. Genes overexpressed in DMPM (n = 68) included calretinin, vitronectin, claudin 15, alpha4 laminin, hyaluronan synthase 1, cadherin 11, RAB7, v-maf, and the epidermal growth factor-containing fibulin-like extracellular matrix protein 1. Genes overexpressed in OC/PPC (n = 121) included insulin-like growth factor II (IGF-II); IGF-II binding protein 3; cyclin E1; folate receptors 1 and 3; RAB25; MUC4; endothelin-1; CD24; kallikreins 6, 7, and 8; claudins 3, 4, and 6; Notch3; and MMP-7. Quantitative real-time PCR validated the differential expression of 13 genes, and immunohistochemistry confirmed the differences for four gene products.
CONCLUSIONS: Expression profiling separates OC/PPC from DMPM and identifies a number of genes that are differentially expressed in these tumors. The molecular signatures unique to OC/PPC and DMPM should provide a molecular basis to study both tumors and new potential markers for facilitating their differential diagnosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17062665     DOI: 10.1158/1078-0432.CCR-06-1059

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  40 in total

1.  PINCH-2 expression in cancers involving serosal effusions using quantitative PCR.

Authors:  Y Yuan; H P Dong; D A Nymoen; J M Nesland; C Wu; B Davidson
Journal:  Cytopathology       Date:  2011-02       Impact factor: 2.073

Review 2.  Laminin isoforms in development and disease.

Authors:  Susanne Schéele; Alexander Nyström; Madeleine Durbeej; Jan F Talts; Marja Ekblom; Peter Ekblom
Journal:  J Mol Med (Berl)       Date:  2007-04-11       Impact factor: 4.599

3.  Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer.

Authors:  Ludmila Szabova; Chaoying Yin; Sujata Bupp; Theresa M Guerin; Jerome J Schlomer; Deborah B Householder; Maureen L Baran; Ming Yi; Yurong Song; Wenping Sun; Jonathan E McDunn; Philip L Martin; Terry Van Dyke; Simone Difilippantonio
Journal:  Cancer Res       Date:  2012-05-22       Impact factor: 12.701

4.  Proteomics of rat prostate lobes treated with 2-N-hydroxylamino-1-methyl-6-phenylimidazo[4,5-b]pyridine, 5alpha-dihydrotestosterone, individually and in combination.

Authors:  Telih Boyiri; Richard I Somiari; Stephen Russell; Cesar Aliaga; Karam El-Bayoumy
Journal:  Int J Oncol       Date:  2009-09       Impact factor: 5.650

Review 5.  Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.

Authors:  Russell Vang; Ie-Ming Shih; Robert J Kurman
Journal:  Adv Anat Pathol       Date:  2009-09       Impact factor: 3.875

6.  Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases.

Authors:  Ben Davidson; Arild Holth; Mai T P Nguyen; Claes G Tropé; Chuanyue Wu
Journal:  Gynecol Oncol       Date:  2012-10-22       Impact factor: 5.482

Review 7.  Pathogenesis of ovarian cancer: clues from selected overexpressed genes.

Authors:  Ie-Ming Shih; Ben Davidson
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

Review 8.  Roles of the first-generation claudin binder, Clostridium perfringens enterotoxin, in the diagnosis and claudin-targeted treatment of epithelium-derived cancers.

Authors:  Yosuke Hashimoto; Kiyohito Yagi; Masuo Kondoh
Journal:  Pflugers Arch       Date:  2016-09-15       Impact factor: 3.657

Review 9.  The emerging role of the RAB25 small GTPase in cancer.

Authors:  Roshan Agarwal; Igor Jurisica; Gordon B Mills; Kwai Wa Cheng
Journal:  Traffic       Date:  2009-07-27       Impact factor: 6.215

10.  Talc use, variants of the GSTM1, GSTT1, and NAT2 genes, and risk of epithelial ovarian cancer.

Authors:  Margaret A Gates; Shelley S Tworoger; Kathryn L Terry; Linda Titus-Ernstoff; Bernard Rosner; Immaculata De Vivo; Daniel W Cramer; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.